Spero Therapeutics Inc
Company Profile
Business description
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Contact
675 Massachusetts Avenue
14th Floor
CambridgeMA02139
USAT: +1 857 242-1600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
32
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,828.70 | 56.70 | 0.65% |
CAC 40 | 7,738.42 | 75.83 | 0.99% |
DAX 40 | 23,790.11 | 116.82 | 0.49% |
Dow JONES (US) | 44,496.34 | 1.40 | 0.00% |
FTSE 100 | 8,774.69 | 10.64 | -0.12% |
HKSE | 24,221.41 | 149.13 | 0.62% |
NASDAQ | 20,359.81 | 156.92 | 0.78% |
Nikkei 225 | 39,762.48 | 223.85 | -0.56% |
NZX 50 Index | 12,784.29 | 49.76 | 0.39% |
S&P 500 | 6,216.09 | 18.08 | 0.29% |
S&P/ASX 200 | 8,597.70 | 56.60 | 0.66% |
SSE Composite Index | 3,454.79 | 2.95 | -0.09% |